inclisiran
Sponsor Novartis AG · listed as NVS
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-10-26
As disclosedOct 26, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05360446
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)Coronary Artery Disease
All tracked catalysts for inclisiran
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-10-26 | READOUT | medium | NCT05360446 |
| 2026-10-31 | READOUT | medium | NCT03705234 |
| 2027-02-11 | READOUT | medium | NCT07102628 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More NVS catalysts